| 许蔡艳,曹莺,严佳栋,等.临床药师用药指导下华法林的抗凝效果与安全性研究[J].安徽医药,2018,22(12):2475-2478. |
| 临床药师用药指导下华法林的抗凝效果与安全性研究 |
| The study on anticoagulation effect and safety of warfarin under the guidance of clinical pharmacists |
| 投稿时间：2018-05-21 |
| DOI： |
| 中文关键词: 华法林 随机对照试验 临床药师 |
| 英文关键词: Warfarin Randomized controlled trial Clinical pharmacist |
| 基金项目: |
|
| 摘要点击次数: 2582 |
| 全文下载次数: 865 |
| 中文摘要: |
| 目的 探讨临床药师参与华法林抗凝治疗的效果与安全性的影响。 方法 2017年1—12月收治的需华法林抗凝治疗的116名患者,采用随机数字表法将患者分成临床药师指导华法林抗凝治疗组61例(观察组)和非临床药师指导华法林抗凝治疗组55例(对照组)。对照组由医师指导用药剂量,护士进行华法林教育,观察组患者在对照组的基础上由2名心血管内科的临床药师进行用药宣教。 结果 两组患者年龄、性别构成、血小板计数及功能、肝肾功能、饮酒史、高血压史、既往出血史、既往卒中史均差异无统计学意义(均P>0.05)。观察组与对照组INR达标率分别为57.31%和38.92%；有效抗凝率分别为40.98%和14.54%；抗凝不足率分别为27.87%和38.67%；抗凝过度率分别为8.70%和12.81%,差异有统计学意义(P<0.05)。观察组与对照组分别有 3和4例患者出现出血事件,观察组有1例出现在抗凝达标后出现脑梗死,观察组不良反应发生率(4.92%)低于对照组(7.27%),但差异无统计学意义。 结论 临床药师参与华法林抗凝治疗可提高INR达标率和有效抗凝率,降低抗凝不足率和抗凝过度率,有助于提高华法林治疗的有效性和安全性。 |
| 英文摘要: |
| Objective To explore the effect and safety of clinical pharmacist-participated anticoagulant therapy of warfarin. MethodsFrom January to December in2017,6 cases of patients with need for warfarin anticoagulant therapy were divided into clinical pharmaceutical guidance group of 61 cases (trial group) and non-pharmaceutical guidance group of 55 cases (control group) by using the random number table.The patients in the control group received warfarin dosage following the visiting doctor′s advice and nurse′s warfarin education.The patients in the trial group were taught about warfarin anticoagulant education by two cardiovascular clinical pharmacists on the basis of the control group. Results There were no statistically significant differences between the two groups in age,gender composition,platelet count and function,liver and kidney function,history of alcohol consumption,history of hypertension,previous bleeding history,and previous stoke history.(all P>0.05).The INR compliance rates in the trial group and the control group were 57.31% and 38.92%,respectively .The effective anticoagulation rates were 40.98% and 14.54%.The anticoagulant deficiency rates were 27.87% and 38.67% and the excessive anticoagulation rates were 8.70% and 12.81%,respectively (P<0.05).There were 3 and 4 patients developed bleeding events in trial group and control group.In the trial group,1 case had cerebral infarction after anticoagulant compliance.The incidence rate of adverse reactions in the trial group (4.92%) was lower than that in the control group (7.27%),however,the difference was not significant. Conclusion The clinical pharmacist-participated warfarin anticoagulant therapy may increase the INR compliance rate and the effective anticoagulation rate,decrease the anticoagulant deficiency rate and the excessive anticoagulation rate,which contribute to increase the effectiveness and safety of warfarin treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
